Hoitt Jason 4

What Happened

• Jason Hoitt, Chief Patient Officer at Stoke Therapeutics, reported derivative activity on March 15, 2026. The filing shows an exercise/conversion (transaction code M) that resulted in 10,000 shares acquired at $0.00 and a concurrent 10,000-share disposition at $0.00. Footnotes describe restricted stock units (RSUs) that convert to one share each and a vesting schedule beginning March 15, 2026.

Key Details

• Transaction date: 2026-03-15; price reported: $0.00 for both the acquisition and the disposition.
• Shares acquired: 10,000 (via exercise/conversion of a derivative). Shares disposed: 10,000 (derivative-related disposition).
• Shares owned after the transactions: not specified in the Form 4 filing.
• Footnotes: F2 notes each RSU equals one share; F3 states the award vests 1/4 annually beginning March 15, 2026. F1 notes an aggregate 2,186 shares were acquired under the issuer’s ESPP in one or more exempt transactions.
• Filing date: 2026-03-17 (filed two days after the transaction date), which appears to be within the standard two-business-day Form 4 deadline.

Context

• The transactions are derivative-conversion activity (RSU settlement) rather than an open-market purchase or sale for cash. The $0.00 price indicates shares were issued/converted rather than bought with cash; the matching disposition at $0.00 likely reflects an administrative transfer related to the derivative settlement (e.g., settlement mechanics or withholding), though the filing does not detail proceeds or tax-withholding specifics. These kinds of RSU conversions are common and do not by themselves indicate a change in insider sentiment.